Long-term Outcomes and Predictors of Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Endarterectomy

Shuai Sun, BS1,2,3,4†, Ji-Feng Li, MD, PhD1,2,3,4†, Lin Liu, MS1,2,3,4, Ran Miao, MD, PhD1,2,3,4, Su-Qiao Yang, MD, PhD1,2,3,4, Tu-Guang Kuang, MD, PhD1,2,3,4, Juan-Ni Gong, MD, PhD1,2,3,4, Song Gu, MD, PhD5, Yan Liu, MD, PhD3, and Yuan-Hua Yang, MD, PhD1,2,3,4†

Abstract

Background: Pulmonary endarterectomy (PEA) is the preferred treatment for CTEPH patients which can significantly improve symptoms and pulmonary hemodynamics. Therefore, this retrospective study evaluated the long-term outcomes after pulmonary endarterectomy (PEA) and analyze the predictors of long-term outcomes for chronic thromboembolic pulmonary hypertension (CTEPH).

Methods: From 2002–2020, 76 CTEPH patients successfully discharged after PEA in Beijing Chaoyang Hospital were followed-up by scheduled clinical visits or telephone interviews. The follow-up time lasted for 18 years and median time was 7.29 years.

Results: The survival rate at 1, 3, 5, 10, 15 years postoperatively was 100.00%, 97.10%, 95.40%, 89.80% and 82.90%, respectively. Multivariate logistics regression analysis showed that postoperative mPAP (hazard ratio: 1.144; 95% confidence interval: 1.018–1.285; \( P = 0.023 \)) was associated with a higher risk of late death, right atrium right and left diameters (hazard ratio: 1.113; 95% confidence interval, 1.006–1.231; \( P = 0.038 \)) were associated with a higher risk of major adverse events.

Conclusion: Pulmonary endarterectomy is an effective way to treat CTEPH. Long-term outcome is excellent for patients who undergoing pulmonary endarterectomy who survived from peri-operation time. Postoperative mPAP is a significant prognostic factor for long-term death and right atrium right and left diameters is a significant prognostic factor for major adverse events. That shows patients with high postoperative mPAP and right atrium right and left diameter should be followed up closely.

Keywords
long-term outcomes, predictors, pulmonary endarterectomy, chronic thromboembolic pulmonary hypertension

Date received: 5 August 2022; revised: 17 October 2022; accepted: 3 November 2022.

1 Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
2 Medical Research Center, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
3 Department of Cardiac Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P.R. China, 100020
4 Department of Respiratory Disease, Capital Medical University, Beijing, P.R. China, 100069
5 Department of Cardiac Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, P.R. China, 100020

† Contributed to this work equally

Corresponding Author:
Yuan-Hua Yang, MD, PhD, Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, 8 GongrenTiyuchangNanlu, Chaoyang District, Beijing, P.R. China. 100020.
Email: yyh1031@sina.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Chronic thromboembolic pulmonary hypertension (CTEPH) is classified into group 4 PH, which is a rare consequence of an acute pulmonary embolism.1,2 The main pathophysiology of CTEPH is pulmonary arterial obstruction by organized thrombotic material stemming from incompletely resolved acute pulmonary embolism.3,5 It was diagnosed as pulmonary hypertension with at least one segmental perfusion defect after at least 3 months of anticoagulation therapy.6 If untreated, patients with a mean pulmonary artery pressure (mPAP) higher than 40 mm Hg were reported to have a 5-year survival rate of less than 30%, and if it exceeds 50 mm Hg, the 5-year survival lowered to about 10%.7,8

Pulmonary endarterectomy (PEA) is the preferred treatment for CTEPH patients which can significantly improve symptoms and pulmonary hemodynamics.9,11 It has been used for over 30 years since the first PEA,12 the surgical technology and procedures are being continuously improved over time so that surgical morbidity and mortality continues to decrease.13 The first PEA operation was done in 2002 in our center and has thus been performed for nearly 20 years until now. In this retrospective study, we reviewed our experience regarding effect, risk factors, long-term outcome of these CTEPH patients who underwent PEA.

In this study, we analyzed factors including basic clinical characteristics (sex, age, body mass index [BMI], smoking), symptoms (hemoptysis, dyspnea, venous thrombus embolism [VTE], WHO functional class), hemodynamics (PAP, pulmonary vascular resistance, cardiac index [CI]), echocardiography (right ventricular basal internal diameter, right atrium right and left diameter, left ventricular end-diastolic internal diameter) and so on.

Methods

Study Population

A retrospective review of our database identified consecutive 76 patients who underwent pulmonary artery endarterectomy for CTEPH and successfully discharged at Beijing Chao-yang hospital between December 2002 and December 2021.

The inclusion criteria for this operation included the following: (1) pulmonary hypertension with evidence of thromboembolic disease on pulmonary angiography, (2) absence of significant noncardiac comorbid diseases (pulmonary sarcoma and other non-CTEPH patients) causing the same clinical and radiological appearance as CTEPH, missing cases during follow up and perioperative death were excluded from the analysis. Due to the retrospective nature of the study, informed consent was waived for data analysis and publication under anonymized form (Figure 1).

Basic Clinical Characteristics and Hemodynamics

The diagnosis of CTEPH was performed using Swan-Ganz catheterization, computed tomography and pulmonary angiography in all cases. Evaluation of heart function using echocardiography and perfusion/ventilation scintigraphy was additionally applied to evaluate perfusion/ventilation mismatch. All patients had significant clinical symptoms, including palpitations, shortness of breath, and intolerance after exercise. Symptoms related to CTEPH were evaluated using WHO functional class and 6MWD preoperatively.

Surgical Procedure/ Surgery

The PEA procedure has been described previously.14 All PEA surgeries were conducted with a median sternotomy and deep hypothermia circulatory arrest (DHCA) with cardiopulmonary bypass (CPB). DHCA is limited to 20-min intervals, and usually one period is enough for the dissection to be completed on each side. The procedure is bilateral, and on completion of the right PEA, bypass is resumed and the patient reperfused while the arteriotomy is closed so that the procedure can be repeated on the left side, with circulatory arrest being initiated as necessary.15 Surgical related date is collected during surgery.

Follow-up and Study Endpoint

Follow-up data were obtained from hospital records and by means of direct telephone interviews with the patients or their families. Follow-up ended when the patient death or until December 2021. The primary follow-up endpoint of this study was all-cause mortality and the secondary endpoint was major adverse events (MAEs), defined as hospitalization resulting from balloon pulmonary angioplasty or giving pulmonary hypertension target medicine due to acute exacerbation.

Statistical Analysis

Continuous variables with a normal distribution are expressed as the mean ± standard deviation (SD) and compared by Student’s t-test, continuous variables with a non-normal distribution were presented as the median and interquartile (IQR) and compared by nonparametric test. Categorical variables are expressed as number with percent and compared by nonparametric test. Estimation of cumulative survival was performed by using the Kaplan–Meier method and compared with the log-rank test. To address factors that are associated with long-term mortality, the missing values impute by multiple imputation. Multivariate logistic regression analysis and Cox proportional hazards analysis were separately performed, respectively. Cox proportional
| Variables                        | All (N = 76) | Late death | Major adverse events | P Value | Major adverse events | P Value |
|---------------------------------|--------------|------------|----------------------|---------|----------------------|---------|
|                                 |              | Yes(n = 7) | No(n = 69)           |         | Yes(n = 10)          |         |
|                                 |              |            |                      |         |                      |         |
|                                 |              |            |                      |         |                      |         |
| Sex, (male, n%)                 | 58(76.32)    | 6(85.71)   | 52(75.36)            | 1.000   | 6(60.00)             | 0.366   |
| Age, y                          | 45.00 ± 11.52| 35.86 ± 10.43| 45.93 ± 11.28       | 0.027   | 52.20 ± 10.20        | 0.033   |
| Bmi, kg/m²                      | 24.39 ± 2.90 | 23.10 ± 3.48| 24.52 ± 2.83        | 0.221   | 23.59 ± 2.89         | 0.357   |
| Smoking, n%                     | 39(51.32)    | 5(71.43)   | 34(49.28)            | 0.432   | 2(20.00)             | 0.074   |
| Albumin, g/L                    | 36.67 ± 3.93 | 35.54 ± 4.10| 36.79 ± 3.92        | 0.428   | 37.63 ± 4.34         | 0.412   |
| Lymphocyte count, 10^9/L        | 1.99(1.68–2.77)| 2.07(1.73–2.76)| 2.01(1.73–2.76) | 0.461   | 1.81(1.56–2.57)      | 0.115   |
| NTproBNP, pg/ml                 | 1115.00(504.95–2178.50)| 1403.30 ± 950.97| 1129.50(440.93–2167.25) | 0.880   | 1187.83 ± 1083.53    | 0.543   |
| Therapeutic anticoagulant, n%   | 75(98.68)    | 7(100)     | 68(98.55)            | 1.000   | 10(100.00)           | 1.000   |
| PAH-specific drugs, n%          | 16(21.05)    | 1(14.29)   | 15(21.74)            | 1.000   | 4(40.00)             | 0.246   |
| Coronary artery bypass grafting, n% | 3(0.04)    | 0(0.00)    | 3(4.35)              | 1.000   | 3(4.55)              | 1.000   |
| Symptoms at admission           |              |            |                      |         |                      |         |
| Time from symptoms to PEA, mo   | 36.00(21.00–60.00)| 38.14 ± 37.48| 36.00(21.50–60.00) | 0.470   | 48.90 ± 32.50        | 0.526   |
| Hemoptysis, n%                  | 25(32.89)    | 4(57.14)   | 21(30.43)            | 0.209   | 3(30.00)             | 22(33.33)| 1.000   |
| dyspnea, n%                     | 76(100)      | 7(100)     | 69(1000)             | 1.000   | 10(100.00)           | 66(100.00)| 1.000   |
| 6MWT, m                         | 383.15 ± 105.13| 336.25 ± 85.11| 386.50 ± 106.25    | 0.360   | 355.71 ± 97.29       | 0.467   |
| WHO functional class(I-II/III-IV), n% | 39/37(51.32/44.68)| 3/4(42.86/57.14) | 36/33(52.17/47.83) | 0.414   | 2/8(20.00/80.00)     | 0.074   |
| VTE, n%                         | 42(55.26)    | 3(42.86)   | 39(56.52)            | 0.694   | 5(50.00)             | 37(56.06)| 0.719   |
| Hemodynamics                    |              |            |                      |         |                      |         |
| Cl, L/min1·m⁻²                  | 1.99(1.65–2.55)| 1.51 ± 0.07| 2.07(1.69–2.57)      | 0.044   | 2.77 ± 1.02          | 2.04 ± 0.67| 0.089   |
| sPAP, mm Hg                     | 90.59 ± 20.30| 79.57 ± 19.19| 91.75 ± 20.20       | 0.132   | 98.40 ± 9.58         | 89.38 ± 21.29| 0.034   |
| dPAP, mm Hg                     | 33.60 ± 8.19 | 31.86 ± 8.26| 33.78 ± 8.23        | 0.558   | 32.60 ± 7.31         | 33.76 ± 8.37| 0.681   |
| mPAP, mm Hg                     | 52.63 ± 10.63| 47.76 ± 10.99| 53.15 ± 10.55       | 0.196   | 54.53 ± 3.96         | 52.32 ± 11.34| 0.254   |
| PVR, dyn.s.cm⁻⁵                 | 908.50(741.00–1180.75)| 1037.00 ± 334.37| 908.50(738.75–1143.75)| 0.747   | 900.78 ± 375.82      | 987.17 ± 332.05| 0.478   |
| Echocardiography                |              |            |                      |         |                      |         |
| Main pulmonary artery internal  | 32.04 ± 4.13 | 30.73 ± 5.75| 32.17 ± 3.96        | 0.423   | 32.51 ± 4.75         | 31.96 ± 4.06| 0.699   |
| diameter, mm                    |              |            |                      |         |                      |         |
| Left ventricular end-diastolic   | 39.68 ± 5.40 | 39.06 ± 7.23| 39.75 ± 5.25        | 0.099   | 40.02 ± 4.12         | 39.63 ± 5.60| 0.833   |
| internal diameter, mm            |              |            |                      |         |                      |         |
| Left ventricular end-systolic    | 23.19 ± 5.01 | 21.73 ± 6.98| 23.35 ± 4.80        | 0.377   | 23.66 ± 4.35         | 23.12 ± 5.13| 0.753   |
| internal diameter, mm            |              |            |                      |         |                      |         |
| Left ventricular end-systolic internal diameter, mm | 72.00(67.00–76.00)| 76.00 ± 9.29| 71.90(67.00–76.00) | 0.225   | 69.00(63.75–76.25)   | 72.00(68.00–76.50)| 0.239   |

(continued)
| Variables                                      | Late death                     | P Value | Major adverse events         | P Value |
|------------------------------------------------|--------------------------------|---------|------------------------------|---------|
|                                                | All (N = 76)                   |         |                              |         |
| ejection fraction (LVEF), %                    |                                |         |                              |         |
| Right ventricular basal internal diameter, mm  | 49.00 (42.00–55.00)            | 44.00 ± 18.28 | 48.91 ± 7.68 | 0.013 | 50.63 ± 7.35 | 48.00 (42.00–55.00) | 0.522 |
| Right atrium right and left diameters, mm      | 50.66 ± 9.60                   | 55.76 ± 9.11 | 50.12 ± 9.56 | 0.141 | 54.90 ± 9.66 | 49.99 ± 9.50 | 0.134 |
| Estimated of pulmonary artery systolic pressure, mm Hg | 95.45 ± 21.75               | 100.26 ± 24.51 | 94.94 ± 21.59 | 0.797 | 100.05 (97.63–107.25) | 94.26 ± 21.65 | 0.265 |
| Postoperative Albumin, g/L                     | 37.45 (34.38–42.63)            | 34.77 ± 5.92 | 37.90 (24.40–43.10) | 0.095 | 35.55 ± 4.07 | 38.20 (34.40–43.15) | 0.075 |
| Lymphocyte count, 10^9/L                       | 1.37 (1.03–1.60)               | 1.29 ± 0.62 | 1.36 (1.04–1.63) | 0.512 | 1.27 ± 0.35 | 1.42 ± 0.50 | 0.354 |
| Postoperative sPAP, mm Hg                      | 49.00 (40.25–60.00)            | 67.00 ± 17.79 | 47.00 (39.00–60.00) | 0.418 | 60.00 (59.00–68.00) | 47.00 (39.00–59.00) | 0.014 |
| Postoperative dPAP, mm Hg                      | 20.69 ± 6.34                   | 25.71 ± 8.18 | 20.13 ± 5.93 | 0.026 | 24.50 ± 9.06 | 20.19 ± 5.83 | 0.227 |
| Postoperative mPAP, mm Hg                      | 30.00 (24.58–37.33)            | 39.48 ± 10.44 | 29.67 (24.33–36.33) | 0.019 | 38.00 ± 12.69 | 30.07 ± 7.98 | 0.016 |
| Postoperative PVR, dyn·s·cm^5                  | 155.00 (127.00–241.75)         | 218.33 ± 136.40 | 156.00 (127.00–239.50) | 0.773 | 251.20 ± 138.76 | 154.00 (127.00–221.00) | 0.504 |

Categorical data are presented as n (%) and continuous data as mean ± standard deviation or median and interquartile.
BMI: body mass index; PEA: pulmonary endarterectomy; VTE: venous thromboembolism; 6MWD: 6 min walking distance; NT-proBNP: N-terminal pro-B-type natriuretic peptide; CI: cardiac index; sPAP: systolic pulmonary artery pressure; dPAP: diastolic pulmonary artery pressure; mPAP: mean pulmonary artery pressure; PVR: pulmonary vascular resistance.
hazards analysis was performed at the time point of 1, 3, 5, 15 years after surgery, and at the end of the follow-up period (overall). The optimal postoperative mPAP cutoff value for adverse events were determined with the aid of a receiver operating characteristic curve.

$P < 0.05$ are considered statistically significant. All statistical analyses were performed with GraphPad Prism Version 8 (GraphPad Software, La Jolla, CA) and SPSS 26.0 software (IBM, Armonk, NY).

**Results**

**Clinical Characteristics of Enrolled Patients**

Baseline characteristics, preoperative hemodynamic and echocardiographic date are shown in Table 1. The average age of the patients was $45.00 \pm 11.52$ years, and $76.32\%$ were male. Before surgery, 16 patients require pulmonary arterial hypertension-targeted treatments. The time from first symptoms to PEA was $36.00(21.00–60.00)$ months. All patients suffered from clinical symptoms preoperatively, there are $37(44.68\%)$ patients classified to WHO class III or IV and $42(55.26\%)$ patients had VTE history.

Hemodynamics at diagnosis showed that mPAP was $52.63 \pm 10.63$ mm Hg and PVR was $908.50(741.00–1180.75)$ dyn.s.cm$^{-5}$, CI was $1.99(1.65–2.55)$ L.min$^{-1}$m$^{-1}$.

Echocardiography findings showed that the main pulmonary artery Internal diameter was $32.04 \pm 4.13$ mm, right ventricular basal internal diameter was $49.00(42.00–55.00)$ mm (Table 1).

**Long-Term Survival**

As shown in Figures 2, 3, the mPAP and PVR were significantly decreased after the surgery. And follow-up ended with interval of $7.29(4.00–8.97)$ years. The longest follow-up period was 18 years and the shortest was 1 year. The survival rate after PEA at 1,3,5,10,15 years was $100\%$, $97.10\%$, $95.40\%$, $89.80\%$ and $82.90\%$, respectively (Figure 4). After the surgery, all patients received oral anticoagulant therapy. Four patients require pulmonary arterial hypertension-targeted treatments, 9 patients received balloon dilatation of pulmonary artery (BPA).

Age ($35.86 \pm 10.43$ VS $45.93 \pm 11.28$; $P = 0.027$) was much younger in those patients died compared with the patients survived. Preoperative CI ($1.51 \pm 0.07$ VS $2.07(1.69–2.57)$, $P = 0.044$) was much lower in those patients died compared with the patients survived. Preoperative right ventricular basal internal diameter ($44.00 \pm 18.28$ VS $48.91 \pm 7.68$, $P = 0.013$) was much lower in those patients died compared with the patients survived. Postoperative dPAP ($25.71 \pm 8.18$ VS $20.13 \pm 5.93$, $P = 0.026$) and mPAP ($39.48 \pm 10.44$ VS $29.67(24.33–36.33)$; $P = 0.019$) was much higher in those patients died compared with the patients survived (Table 1).

**Major Adverse Events**

The incidence of MAEs is $13.16\% (10/76)$. Age ($52.20 \pm 10.20$ VS $43.91 \pm 11.38$; $P = 0.033$) was higher in those patients occurred MAEs compared with the patients no MAEs occurred. Right atrium right and left diameters ($54.90 \pm 9.66$ VS $49.99 \pm 9.50$; $P = 0.134$) has no significant difference in those patients.
And postoperative mPAP (38.00 ± 12.69 VS 30.07 ± 7.98; \( P = 0.016 \)) was much higher in those patients with MAEs (Table 1).

### Multivariate Logistic Regression

Multivariate logistic regression analysis showed that age, perioperative mPAP and postoperative mPAP were predictors in late death. After adjusted for sex, age (HR:0.898, 95%CI:0.809–0.997, \( P = 0.045 \)) and postoperative mPAP (HR:1.144, 95% CI:1.018–1.285, \( P = 0.023 \)) were independent predictors in late death (Table 2). Postoperative mPAP (HR:1.145, 95% CI:1.041–1.259, \( P = 0.005 \)) was an independent predictor in primary endpoint event. After adjusted for sex, right atrium right and left diameters (HR:1.133, 95%CI:1.006–1.231, \( P = 0.038 \)) was an independent predictor in MAEs.

The cut-off value was determined with ROC curve and Youden index. ROC curve analysis indicated that postoperative mPAP 40.50mm Hg was a cut off value of death (\( P = 0.019 \); the area under the ROC curve was 0.771) (Figure 5).

### Discussion

This is the first study evaluating nearly 20 years outcomes of CTEPH patients after PEA in China. The results of this retrospective analysis demonstrate the prognostic impact of long-term outcomes, which can provide a reference for PEA treatment.

PEA is the preferred treatment of choice for operable patients with CTEPH with excellent long-term outcome.\(^9,16,17\) During a recent study in France, PVR, CO and TLCO can predict postoperative outcomes.\(^18\) In our study, age, perioperative mPAP, postoperative mPAP were significant predictors for death. However, after sex and age adjustment, only postoperative is an independent predictor for death. This suggests that not only postoperative status can affect the outcome.

It was observed that postoperative mPAP can affect late death. There has been an imaging data of pulmonary vascular study indicating that 20% of the pulmonary vasculature abnormal with new vascular lesions involved even with regular anticoagulation therapy.\(^19,20\) This demonstrates that residual PH remains an important factor in the survival. In our center, the incidence of residual pulmonary hypertension was 22.4%. In this study, we calculate mPAP=40.5mm Hg is the cutoff value for postoperative death. In ERS statement on CTEPH, mPAP\(\geq 38\)mm Hg can affect the patient long-term outcome,
mPAP>30mm Hg as a suggest threshold to initiate drug therapy.9

The incidence of VTE varied in different studies, especially in CTEPH cohort. The incidence of DVT in a UK registry study was 59.3% to 60.4% in PEA patients. The incidence of PE/DVT is 63.8/48.3, 69.8/36.7, 39.1/43.5% respectively in America, Europe and Japan in the worldwide prospective CTEPH Registry.21 The incidence of VTE was 55.2% in our study, within the scope of reported literatures.

A small number of studies have considered that elderly patients should be offered PEA in expert center.22,23 In a recent study, the patients were split into three groups according to their age: group1: ≤50 years, group2: >50≤70 years, group3: >70 years, they find that survival of the group1 patients were better than group2 patients and group2 patients were better than group3 patients with 5 years follow up.24 In our center, the age is an independent risk factor of long-term outcome, and all-cause mortality patients were younger, this may be relevant to older patients received BPA and drug treatment. In our center, one patient was very young at the time of the operation, and dead after about 10 years, because this patient has patent foramen ovale and drugs abuse history. This may influence the results on age.

This study is a retrospective observational design. There are several limitations: 1) Sample sized is limited. 2) The follow-up time varies too much between different patients. 3) For the limitation of target medicine, only 16 patients received pulmonary arterial hypertension-targeted treatments before PEA and 4 patients received pulmonary arterial hypertension-targeted treatments after PEA 4) Previous studies suggest that sex-related survival difference in CTEPH patients who underwent PEA, there are more males than females in PEA patients in our center, this may affect the all-cause mortality rate.

Conclusion

In conclusion, our study shows that PEA can improve hemodynamic effectively and the patients have excellent long-term prognosis. And residual pulmonary hypertension can affect the survival of patients.

Acknowledgements

Not applicable

Author Contributions

Shuai Sun and Ji-Feng Li conceived and designed the research and acquired the data. Jia-Yu Liu and Lin Liu performed statistical analyses. Ran Miao Su-Qiao Yang, Tu-Guang Kuang, Juan-Ni Gong, Song Gu, Yan Liu contributed to the interpretation of data. Shuai Sun and Ji-Feng Li drafted the manuscript. Yuan-Hua Yang made critical revision of the manuscript for key intellectual content and have seen and approved the final version.

Consent for Publication

All authors have viewed the manuscript and written informed consent for publication was obtained from all participants.

Data Availability

The data will not be shared, because the identified participants information is included in the data.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethics Approval and Consent to Participate

Verbal informed consent was obtained from the patient(s) for their anonymized information to be published in this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Natural Science Foundation of China (grant number 31670928), and Reform and Development program of Beijing Institute of Respiratory Medicine.

ORCID iDs

Yuan-Hua Yang https://orcid.org/0000-0003-0293-6737

References

1. Papamatheakis DG, Poch DS, Fernandes TM, et al. Chronic thromboembolic pulmonary hypertension: JACC focus seminar[J]. J Am Coll Cardiol. 2020;76(18):2155-2169. DOI:10.1016/j.jacc.2020.08.074
2. Simonneau G, Montani D, Celemajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension[J]. Eur Respir J. 2019;53(1):1801913. DOI:10.1183/13993003.01913-2018
3. Küçükoğlu MS. Ten year outcome of chronic thromboembolic pulmonary hypertension patients in a Tertiary University Hospital[J]. Anatol J Cardiol. 2020;23(2):105-109. DOI: 10.14744/anatoljcardiol.2019.9329
4. Lang IM, Campean IA, Sadushi-Kolici R, et al. Chronic thromboembolic disease and chronic thromboembolic pulmonary hypertension [J]. Clin Chest Med. 2021;42(1):81-90. DOI:10.1016/j.ccm.2020.11.014
5. Simonneau G, Dorfmuller P, Guignabert C, et al. Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology[J]. Ann Cardiothorac Surg. 2022;11(2):106-119. DOI:10.21037/acs-2021-pte-10
6. Mandras SA, Mehta HS, Vaidya A. Pulmonary hypertension: a brief guide for clinicians[J]. Mayo Clin Proc. 2020;95(9):1978-1988. DOI:10.1016/j.mayocp.2020.04.039
7. Sakurai Y, Takami Y, Amano K, et al. Predictors of outcomes after surgery for chronic thromboembolic pulmonary hypertension[J]. Ann Thorac Surg. 2019;108(4):1154-1161. DOI:10.1016/j.athoracsur.2019.03.100
8. Hirakawa K, Yamamoto E, Takashio S, et al. Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension[J]. Cardiovasc Interv Ther. 2022;37(1):60-65. DOI:10.1007/s12928-021-00775-6
9. Delcroix M, Torbicki A, Gopalan D, et al. ERS statement on chronic thromboembolic pulmonary hypertension[J]. Eur Respir J. 2021;57(6):2002828. DOI:10.1183/13993003.02828-2020

10. Tzoumas A, Peppas S, Sagris M, et al. Advances in treatment of chronic thromboembolic pulmonary hypertension[J]. Thromb Res. 2022;212:30-37. DOI:10.1016/j.thromres.2022.02.003

11. Kim NH, Delcroix M, Jais X, et al. Chronic thromboembolic pulmonary hypertension[J]. Eur Respir J. 2019;53(1):1801915. DOI:10.1183/13993003.01915-2018

12. Nierlich P, Hold A, Ristl R. Outcome after surgical treatment of chronic thromboembolic pulmonary hypertension: Dealing with different patient subsets. A single-centre experience[J]. Eur J Cardiothorac Surg. 2016;50(5):898-906. DOI:10.1093/ejcts/ezw099

13. Papakonstantinou NA, Kampaktsis PN, Rorris FP, et al. Surgical treatment of pulmonary embolism and chronic thromboembolic pulmonary hypertension[J]. Curr Pharm Des. 2022;28(7):521-534. DOI:10.2174/1381612827666210902152539

14. Li JF, Wu LJ, Wen GY, et al. Platelet count trends and response to fondaparinux in a cohort of heparin-induced thrombocytopenia suspected patients after pulmonary endarterectomy[J]. J Thromb Thrombolysis. 2021;51(3):703-710. DOI:10.1007/s11239-020-02260-y

15. Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH)[J]. Circulation. 2011;124(18):1973-1981. DOI:10.1161/circulationaha.110.015008

16. Jenkins D, Madani M, Fadel E, et al. Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension [J]. Eur Respir Rev. 2017;26(143):160111. DOI:10.1183/16000617.0111-2016

17. Ranka S, Mohananey D, Agarwal N, et al. Chronic thromboembolic pulmonary hypertension-management strategies and outcomes[J]. J Cardiothorac Vasc Anesth. 2020;34(9):2513-2523. DOI:10.1053/j.jvca.2019.11.019

18. Tromeur C, Jais X, Mercier O, et al. Factors predicting outcome after pulmonary endarterectomy[J]. PLoS One. 2018;13(6):e0198198. DOI:10.1371/journal.pone.0198198

19. Braams NJ, Ruijgrok D, Schokker MGM, et al. Pulmonary vascular imaging characteristics after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension[J]. J Heart Lung Transplant. 2020;39(3):248-256. DOI:10.1016/j.healun.2019.11.020

20. Ruijgrok D, Braams NJ, Nossent EJ, et al. Dynamic vascular changes in chronic thromboembolic pulmonary hypertension after pulmonary endarterectomy[J]. Pulm Circ. 2020;10(4):2045894020907883

21. Guth S, D’armini AM, Delcroix M, et al. Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry[J]. ERJ Open Res. 2021;7(3):00850-2020. DOI:10.1183/23120541.00850-2020

22. Newnham M, Hernandez-Sanchez J, Dunning J, et al. Age should not be a barrier for pulmonary endarterectomy in carefully selected patients[J]. Eur Respir J. 2017;50(6):1701804. DOI:10.1183/13993003.01804-2017

23. Berman M, Hardman G, Sharples L, et al. Pulmonary endarterectomy: outcomes in patients aged >70[J]. Eur J Cardiothorac Surg. 2012;41(6):e154-e160. DOI:10.1093/ejcts/ezs188

24. Wiedenroth CB, Bandorski D, Ariobi K, et al. Does age matter? Pulmonary endarterectomy in the elderly patient with CTEPH[J]. Thorac Cardiovasc Surg. 2022. DOI:10.1055/s-0041-1740559